Endosense said that TactiCath is the second generation product which was recently granted CE mark and was unveiled at the DGK 2010, German Cardiac Society meeting in Mannheim, Germany.

Key additions to the second generation TactiCath were based on the valuable input of early clinical adopters and are intended to optimize the utility and versatility of the catheter and the system in clinical practice.

The TactiSys system, which is comprised of a graphical user interface, base station and splitter, was upgraded to include a number of features, like: A customizable, information-rich user interface that displays force-time interval, a new parameter which research has shown may be a better predictor of lesion size than current alternative parameters and automatically generated summary reports that document therapy delivery, including a histogram that shows physicians the forces applied throughout the catheter ablation procedure.

The new TactiCath and TactiSys are indicated for the treatment of atrial fibrillation (AF) and supraventricular tachycardia (SVT). The product is currently available in major markets across Europe, Latin America, Canada, the Middle East and Africa.

Eric Le Royer, president and chief executive officer of Endosense, said: “The new generation was designed in response to customer feedback to create an even more valuable clinical experience with the TactiCath for the treatment of the of cardiac arrhythmias.”

Dipen Shah, MD of University Hospital of Geneva, Switzerland, said: “As a long-time user of the TactiCath, I find the next generation product to be a significantly enhanced system that delivers even greater performance and flexibility during catheter ablation procedures.

“The new features and product enhancements make the TactiCath and TactiSys an even more compelling addition to the EP lab. They reflect a keen understanding by Endosense of our needs and a desire to continuously improve their products.”